Paul: LungLife AI is a diagnostics company focused on the early detection of lung cancer from a simple blood draw, all enhanced by artificial intelligence. Now we believe at Lung Life that we have a technology that can help with this problem called the LungLB® test.
It all starts off with a simple blood draw, and there we're looking for circulating tumor cells. These are bits of the tumor that enter the bloodstream and try and spread to other parts of the body, a process known as metastasis. And this is something that is known to happen early on in lung cancer. What that means is our technology fits within the current clinical care pathway, just another tube of blood and doesn't disrupt the process. So what are the next steps for Lung Life?
Well, based on the strength of the results of our pilot study, we have initiated a pivotal validation study where we're looking to enroll between 400 and 500 patients to test the performance of the LungLB® assay before this test can be available to physicians and their patients, we're enrolling patients in a pivotal validation study based on the strength of the results in our pilot study. So we're looking to enroll between 400 and 500 patients over the next 12 to 18 months where we can validate the technology, understand its performance, and award demographically diverse population. Following our pivotal validation study, the LungLB® tests will be widely available and performed in our CLIA certified laboratory in Thousand Oaks, California. At Lung Life our purpose is simple to be a driving force in the early detection of lung cancer.